Zoetis Receives European Commission Approval for Stronghold® Plus
February 15 2017 - 4:30PM
Business Wire
- A new topical parasiticide for cats
combines the active ingredient in Stronghold – selamectin – with
sarolaner for broadened and extended spectrum of protection
- Company introduces first combination
product building on its sarolaner platform in the $4.2 billion
companion animal parasiticide market
Zoetis Inc. (NYSE:ZTS) today announced that the European
Commission has granted the company a license for Stronghold® Plus
(selamectin/sarolaner), a topical combination of parasiticides that
treats ticks, fleas, ear mites, lice and gastrointestinal nematodes
and prevents heartworm disease in cats.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170215006296/en/
The European Commission has granted
Zoetis Inc. a license for Stronghold® Plus (selamectin/sarolaner),
a topical combination of parasiticides that treats ticks, fleas,
ear mites, lice and gastrointestinal nematodes and prevents
heartworm disease in cats. (Photo: Zoetis)
Veterinarians across the European Union now have a treatment
choice that leverages the benefits of sarolaner, a new innovation
in the class of isoxazolines, without sacrificing the broad
spectrum protection, safety or ease of use they expect.
”The approval of Stronghold Plus enables Zoetis to offer
veterinarians a new topical choice that treats the parasites
commonly presenting a threat to cats with one convenient monthly
dose,” said Dr. Catherine Knupp, Executive Vice President and
President, Research and Development at Zoetis. “For the first time,
we have combined our new, versatile parasiticide sarolaner with the
active ingredient in Stronghold, selamectin, resulting in the first
approval of sarolaner for use in cats. We see sarolaner as a
promising platform for future product lines and lifecycle
innovations and are pleased with the positive data that sarolaner
and its combination continue to generate in studies.”
The market for companion animal parasitic medicines was valued
at more than $4.2 billion in 2015, with a compound annual growth
rate of about 5% over the previous five years, according to
Vetnosis1.
Domenico Otranto, Professor of Parasitology at The University of
Bari in Italy, who recently reviewed the product data of Stronghold
Plus, said: “A number of laboratory and field studies show the
efficacy of the single spot-on application of Stronghold Plus for
at least one month. Veterinarians in the European Union will now
have a very effective option for the treatment and control of four
prominent species of ticks commonly found on cats while maintaining
proven efficacy against fleas, GI worms, heartworms, ear mites and
lice. Ultimately, pet owners and practitioners have a new tool for
improving the health and welfare of cats.”
Dr. Michael Stegemann, Senior Director of Veterinary Research
and Development at Zoetis, said: “Stronghold Plus was entirely
discovered and developed by Zoetis scientists. It provides fast,
sustained coverage from the fleas and ticks most often found on
cats. The combined action of sarolaner and selamectin allows
Stronghold Plus to kill four species of ticks, and it lengthens the
duration of protection against fleas to five full weeks with no
drop in efficacy at the end of the dosing period -- all without
sacrificing protection from other important internal and external
feline parasites. We’re excited to be able to bring this innovation
to veterinarians across the European Union.”
About Stronghold Plus product efficacy and safety:
The active substances in Stronghold Plus are selamectin and
sarolaner, a new combination of parasiticides. Selamectin has
adulticidal, ovicidal and larvicidal activity against fleas
(Ctenocephalides spp). Selamectin is also active against ear mites,
lice, gastrointestinal nematodes and prevents heartworm disease
through its efficacy against Dirofilaria immitis larvae. Sarolaner
is a new acaricide and insecticide belonging to the isoxazoline
class: it is efficacious against ticks, fleas and mites. The most
common side effects of Stronghold Plus are mild and transient
pruritus at the application site. Mild to moderate alopecia at the
application site, erythema and drooling have been uncommonly
observed.
For more information about Stronghold Plus, click here.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 60 years of experience in animal health, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and
medicines, complemented by diagnostic products and genetic tests
and supported by a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries. In 2015, the company generated annual revenue of $4.8
billion with approximately 9,000 employees. For more information,
visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect the current views of
Zoetis with respect to business plans or prospects, expectations
regarding products and other future events. These statements are
not guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2015, including in the sections thereof captioned
“Forward-Looking Statements and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
1 Vetnosis, Animal Health Service:
Parasiticides Report (Sept. 2016)
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170215006296/en/
Zoetis Inc.Media:Anne-France Quentric, +32
227468311anne-france.quentric@zoetis.comorElinore White,
1-973-443-2835elinore.y.white@zoetis.comorInvestor:Steve
Frank, 1-973-822-7141steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024